{
  "id": 17202030,
  "title": "BioVersys initiates Phase 2b trial for anti infective drug BV100",
  "url": "https://urgent.news/2026/10/30/bioversys-initiates-phase-2b-trial-for-anti-infective-drug-bv100",
  "topic": "business",
  "section": "Business",
  "published": "2026-10-30T07:50:06.000Z",
  "source": {
    "name": "Vietnam Investment Review",
    "slug": "vietnam-investment-review",
    "url": "https://vir.com.vn/bioversys-initiates-phase-2b-trial-for-anti-infective-drug-bv100-164008.html"
  },
  "original_language": "en",
  "account": "BioVersys AG, a clinical-stage biopharmaceutical company based in Switzerland, has initiated a Phase 2b trial for its anti-infective drug BV100. The trial, named RIV-CARE, aims to test the effectiveness of BV100 in combination with low-dose polymyxin B against hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex. The study is expected to enroll around 100 patients across multiple geographies and compare the efficacy of BV100 plus low-dose polymyxin B with best available therapy. The trial, conducted by the ADVANCE-ID clinical trial network, is supported by funding from Wellcome, a UK-based global health organization. BioVersys CEO Dr. Marc Gitzinger expressed optimism about the trial's potential to provide real-world evidence for clinical practice in settings with high drug resistance levels.",
  "summary": "Biotechnology company BioVersys enrolled the first patient in its Phase 2b trial evaluating anti infective drug candidate BV100 for treating drug resistant bacterial pneumonia",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}